Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success

Analysts said upcoming data on Pfizer's obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.

from Health and Science https://ift.tt/VJaSF7x
https://ift.tt/9Fx6nyb
https://ift.tt/r1Bs8g2